About Cessation Therapeutics
Cessation Therapeutics is a private company based in Dallas, Texas, incorporated in 2022 in Delaware. It has reported $6,755,000 raised in two offerings on Form D since May 2022. Its chief executive is Andrew Barrett.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Mar 29, 2024 | Apr 3, 2024 | $1,000,000fully sold | 2 | $500K | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| May 2, 2022 | May 11, 2022 | $5,755,000of $10.0M target | 31 | $185K | Equity, Options, Securities on exerciseRule 506(c) | Form D ↗ |
| Total, two offerings | $6,755,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Cessation Therapeutics's Form D filed Apr 3, 2024.
AB
ST
Sharon Tetlow
Director
JH
John Harkey
Director
DF
Daniel Fine
Director
JS
Jay Shepard
Director
MP
Mark Pearson
Director
Earlier filings also listed Eric Rasmussen (executive officer, last listed May 2022) and David Genecov (director, last listed May 2022).